These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30822171)

  • 1. Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases.
    Ferguson SK; Pak DI; Hopkins JL; Harral JW; Redinius KM; Loomis Z; Stenmark KR; Borden MA; Schroeder T; Irwin DC
    Drug Deliv; 2019 Dec; 26(1):147-157. PubMed ID: 30822171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants.
    Butz N; Porté C; Courrier H; Krafft MP; Vandamme TF
    Int J Pharm; 2002 May; 238(1-2):257-69. PubMed ID: 11996829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of ambrisentan.
    Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
    Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
    Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
    J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
    Vizza CD; Fedele F; Pezzuto B; Rubin LJ
    Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
    Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Emulsion Composition on Pulmonary Tobramycin Delivery During Antibacterial Perfluorocarbon Ventilation.
    Orizondo RA; Fabiilli ML; Morales MA; Cook KE
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):251-9. PubMed ID: 26741303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solnatide Demonstrates Profound Therapeutic Activity in a Rat Model of Pulmonary Edema Induced by Acute Hypobaric Hypoxia and Exercise.
    Zhou Q; Wang D; Liu Y; Yang X; Lucas R; Fischer B
    Chest; 2017 Mar; 151(3):658-667. PubMed ID: 27815150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of hypoxic pulmonary vasoconstriction prevent high-altitude pulmonary edema in rats.
    Berg JT; Ramanathan S; Swenson ER
    Wilderness Environ Med; 2004; 15(1):32-7. PubMed ID: 15040504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H
    Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to hypoxia results in uneven pulmonary blood flow distribution prior to pulmonary edema.
    Urano T; Kuwahira I; Iwamoto T; Kamiya U; Ohta Y; Wood JG; Gonzalez NC
    Tokai J Exp Clin Med; 2005 Dec; 30(4):193-202. PubMed ID: 16482939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-performance reoxygenation from PLGA-PEG/PFOB emulsions: a feedback relationship between ROS and HIF-1α.
    Wang J; Wang R; Li N; Shen X; Huang G; Zhu J; He D
    Int J Nanomedicine; 2018; 13():3027-3038. PubMed ID: 29861634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.